MedTrace Logo

A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG Patients

NCT04346888 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-03-08

No results posted yet for this study

Summary

Primary Objectives: To investigate the efficacy of HBM9161 in patients with attack of MG in China

Conditions

Interventions

DRUG

HBM9161 Injection (680mg and 340 mg)

HBM9161 Injection (680mg and 340mg)

DRUG

Placebos

Placebo, HBM9161 Injection (340mg)

DRUG

HBM9161 Injection (340 mg)

HBM9161 Injection (340 mg)

Sponsors & Collaborators

  • Harbour BioMed (Guangzhou) Co. Ltd.

    lead INDUSTRY

Principal Investigators

  • Chongbo Zhao · Huashan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-23
Primary Completion
2021-08-24
Completion
2021-08-24

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04346888 on ClinicalTrials.gov